文献速递慢性静脉疾病

氰基丙烯酸酯胶黏剂消融治疗大隐静脉功能不全的系统评价与荟萃分析

Systematic review and meta-analysis of endovenous cyanoacrylate adhesive ablation for incompetent saphenous veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-01-06

该系统评价与荟萃分析评估氰基丙烯酸酯消融(CA)治疗大隐静脉功能不全的有效性、安全性与医疗质量,纳入3项比较研究(2项随机对照试验、1项观察性研究,共1057例)及10项病例系列作安全性评估。结果显示CA与射频消融(RFA)、腔内激光消融(EVLA)有效性相当,但12个月随访不良事件更少、更轻,且术中疼痛更轻、手术与恢复时间更短,无需肿胀麻醉与弹力绷带。

要点

  • CA与RFA、EVLA在降低疾病严重程度方面有效性相当,无显著优劣。
  • CA在12个月随访时不良事件更少、严重程度更轻,主要不良事件无差异。
  • CA术中疼痛更轻、手术与恢复时间更短,无需肿胀麻醉和术后弹力绷带。

核心结论

  • 与EVLA和RFA相比,CA治疗有效性结果相当,轻度不良事件更少更轻,主要不良事件无差异。
  • CA在医疗质量指标上具优势,包括术中疼痛、治疗与恢复时间、麻醉使用更少及术后零弹力绷带使用。

研究设计与样本

  • 系统评价与荟萃分析,采用GRADE框架,并用Cochrane偏倚风险工具评估随机临床试验质量。
  • 有效性评估纳入3项比较研究(2项随机对照试验和1项观察性研究),共1057例参与者。
  • 安全性评估另纳入10项病例系列,证据仅支持CA与RFA、EVLA比较。

主要发现

  • 三种治疗均降低疾病严重程度,但有效性方面无一种显著优于其他。
  • 12个月随访时CA器械的不良事件少于EVLA或RFA,且严重程度更轻。
  • 患者报告CA术中疼痛少于RFA或EVLA,手术与恢复时间更短。
  • CA无需肿胀麻醉和弹力绷带,较热消融技术更舒适。

临床怎么用

  • 对原发性大隐静脉功能不全,CA可作为与RFA、EVLA有效性相当的选项,且轻度不良事件更少。
  • CA适合关注术中疼痛、恢复时间及希望避免肿胀麻醉和术后弹力绷带者。

局限性

  • 有效性证据仅来自3项比较研究,且仅能与RFA和EVLA比较,无法与其他治疗比较。
  • 安全性评估依赖病例系列,证据等级受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to assess the effectiveness, safety, and quality of care afforded by cyanoacrylate ablation (CA) vs existing options in treating great saphenous vein incompetence. METHODS: We conducted a systematic review; used the Grading of Recommendations Assessment, Development, and Evaluation framework; assessed the quality of randomized clinical trials using the Cochrane risk of bias tool; and performed a meta-analysis on the available comparative measurements. RESULTS: Three comparative studies, two randomized controlled trials and one observational study comprising 1057 participants, were included for effectiveness assessment purposes. The safety assessment also included 10 case series. Available evidence allowed comparison of CA with radiofrequency ablation (RFA) and endovenous laser ablation (EVLA) but not with other treatments. The comparative effectiveness analysis showed that whereas all three treatments reduced disease severity, none was significantly better than any other in terms of effectiveness. In terms of safety, however, CA devices gave rise to fewer adverse events and less severity at 12 months of follow-up than did EVLA or RFA. Other important advantages of CA over EVLA or RFA were linked to quality of care; patients reported less pain during intervention with CA than with RFA or EVLA devices and registered shorter intervention and recovery times. Furthermore, tumescent anesthesia and compression bandages were not necessary, making this technique more comfortable for the patients than endothermal techniques. CONCLUSIONS: Compared with EVLA and RFA, CA treatments yield comparable effectiveness outcomes and lead to less frequent and fewer mild adverse events, without difference in major adverse events. Furthermore, CA devices have advantages in terms of quality of care indicators, such as pain during intervention, treatment and recovery times, lower use of anesthesia, and zero use of compression bandages after treatment.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. García-Carpintero E, Carmona M, Chalco-Orrego JP, et al. Systematic review and meta-analysis of endovenous cyanoacrylate adhesive ablation for incompetent saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 31917181. doi:10.1016/j.jvsv.2019.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。